NERLYNX Launches in Thailand as New HER2+ Breast Cancer Treatment Option
核心洞察
NERLYNX (neratinib) received Thai FDA (搜索) approval in December 2024 for treating early-stage and advanced HER2+ breast cancer (搜索) patients.
Clinical trials demonstrate the oral therapy reduces recurrence risk by up to 42% in hormone receptor-positive patients when started within 12 months of trastuzumab completion.
The drug addresses a significant unmet need in Thailand, where breast cancer (搜索) affects over 20,000 women annually and HER2 (搜索)+ tumors carry increased risk of metastasis and recurrence.
Eligible women with HER2+ breast cancer (搜索) in Thailand now have access to NERLYNX® (neratinib), an oral therapy that significantly reduces cancer recurrence risk and improves disease-free survival. The Thai FDA (搜索) approved the treatment in December 2024, marking the first availability of this targeted therapy in the country.
The approval covers two distinct indications: as a single agent for extended adjuvant treatment of early-stage hormone receptor positive HER2+ breast cancer (搜索) patients who completed trastuzumab-based therapy within the past year, and in combination with capecitabine for advanced or metastatic HER2+ breast cancer patients who have received two or more prior anti-HER2 (搜索) regimens.
Addressing Critical Treatment Gap
Approximately 15-25% of all breast cancer (搜索) tumors are HER2 (搜索)+, a subtype associated with increased risk of metastasis, disease recurrence, and decreased overall survival. Despite treatment advances, an estimated 26% of HER2+ breast cancer (搜索) patients experience disease recurrence following trastuzumab therapy.
"Breast cancer (搜索) remains the most prevalent cancer among Thai women, with over 20,000 new cases diagnosed annually, and more than 4,800 deaths occurring each year," said Dr. Bhuvana Ramaswamy, ST Medical Lead for Southeast Asia. "In patients with early or metastatic HER2+ breast cancer (搜索), the risk of disease progression and recurrence is a significant concern, despite prior treatment with anti-HER2 (搜索) therapies."
The disease burden in Thailand has grown substantially, with breast cancer (搜索) incidence rates doubling over the past two decades from 17.8 per 100,000 in 1998 to 35.7 per 100,000 in 2020. In 2022, breast cancer accounted for 23.2% of all new cancer diagnoses in Thai women, with 21,628 cases diagnosed that year.
Clinical Evidence Supporting Approval
The ExteNET Phase III trial provided pivotal evidence for NERLYNX's efficacy in early-stage disease. This double-blind, placebo-controlled study randomized 2,840 patients across 41 countries with early-stage HER2+ breast cancer (搜索) who had completed adjuvant trastuzumab treatment.
After median follow-up of 5.2 years, neratinib demonstrated a 27% reduction in risk of invasive disease recurrence or death versus placebo (hazard ratio = 0.73, p = 0.008). The five-year invasive disease-free survival rate reached 90.2% for the neratinib arm compared to 87.7% for placebo.
Subgroup analysis revealed even greater benefits for hormone receptor-positive patients who initiated neratinib within 12 months of completing trastuzumab therapy, showing a 42% reduction in recurrence risk and 59% reduction in central nervous system recurrence or death.
For advanced disease, the NALA Phase III trial compared neratinib plus capecitabine (N+C) against lapatinib plus capecitabine (L+C) in 621 patients with centrally confirmed HER2 (搜索)+ metastatic breast cancer (搜索) across 203 sites in 28 countries. The N+C combination significantly improved mean progression-free survival by 2.2 months over L+C treatment, with longer treatment response duration (8.5 months versus 5.6 months) and up to 24% reduction in disease progression or death risk.
Mechanism and Safety Profile
NERLYNX functions as an irreversible tyrosine kinase inhibitor that blocks signal transduction through epidermal growth factor receptors HER1 (搜索), HER2 (搜索), and HER4 (搜索). The oral tablet works by binding to multiple receptors inside cancer cells, blocking growth and multiplication signals.
The most common adverse reactions in the ExteNET trial included diarrhea, nausea, abdominal pain, fatigue, vomiting, rash, stomatitis, decreased appetite, muscle spasms, dyspepsia, liver enzyme increases, nail disorders, dry skin, abdominal distention, nosebleeds, weight decrease, and urinary tract infections.
Market Introduction Strategy
Specialised Therapeutics (搜索) is launching NERLYNX in Thailand under exclusive license from Puma Biotechnology. The company established a dedicated local field team to connect with oncologists nationwide, demonstrating commitment to improving breast cancer (搜索) patient outcomes.
"We are thrilled to be able to make this therapy available to eligible patients with HER2+ breast cancer (搜索) in Thailand for the first time, providing a treatment option that can protect against progression or recurrence in either the early or advanced stages of their disease," said Carlo Montagner, ST Chief Executive Officer.
NERLYNX has received approval for treating certain HER2+ breast cancer (搜索) patients in more than 40 countries outside the United States, including the European Union, China, Latin America, Australia, Canada, and Hong Kong. The Thailand launch represents the first therapy introduction by Specialised Therapeutics (搜索) in the country, responding to local oncologists' need for new treatment options to reduce cancer recurrence and relapse in HER2+ breast cancer patients.